By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On December 28, 2023, CytoSorbents (NASDAQ:CTSO) announced an update on the initial data analysis of the primary safety and ...

WOBURN, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic ...

Cost-effectiveness: Many of these tools offer affordable pricing plans, making advanced data analysis accessible to businesses of all sizes. Here’s how to get started with AI to analyze your data.

Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001) in which initial data analysis indicates a marked reduction in both systemic and ...